Table 1

Investigations on admission to level 2 or 3 care

Time point	Investigations on admission to level 2 or 3 care (HDU or ITU)
Time point	Confirmed or suspected COVID-19*		Non-COVID-19 ARDS†
Routinely on admission	CAP screen	Bronchoscopy‡	CAP screen	Bronchoscopy§
	Echocardiogram	CT thorax±CTPA	Echocardiogram	CT thorax±CTPA
	Autoimmune screen		Autoimmune screen
Routinely on admission, repeated if clinically indicated	Procalcitonin	Troponin	Procalcitonin	Troponin
Routinely on admission, repeated if clinically indicated	Circulating biomarkers of HLH-like syndrome		Circulating biomarkers of HLH-like syndrome

For each survey question, median scores were calculated with a score of <3.5 being considered inappropriate (red background), ≥3.5 and <6.5 uncertain (amber background) and ≥6.5 appropriate (green background).
*In the context of the pandemic.
†Outside the context of the pandemic.
‡Denotes disagreement (disagreement index >1).
§Bronchoscopy if intubated.
ARDS, acute respiratory distress syndrome; CAP, community-acquired pneumonia (microbiology screen); CTPA, CT pulmonary angiogram; HDU, high dependency unit; HLH, haemophagocytic lymphohistiocytosis markers (ie, lactate dehydrogenase, ferritin); ITU, intensive therapy unit.